Effect of Hypertonic Sodium Chloride on Urinary Biomarkers in Healthy Subjects and Patients With Chronic Kidney Disease (CASE)
Primary Purpose
Nephropathy
Status
Completed
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
hypertonic saline
Sponsored by
About this trial
This is an interventional diagnostic trial for Nephropathy focused on measuring Nephrology, chronic kidney disease, sodium-channels, water-channels, BCM
Eligibility Criteria
Inclusion Criteria:
healthy subjects
- healthy males and females
- age 18-70
- BMI range 18,5-30,0 kg/m2
Patients with CKD
- age 18-70
- eGFR 15-60 ml/min
- BMI range 18.5 - 30.0 kg/m2
Exclusion Criteria:
healthy subjects
- hypertension (ie ambulatory BP >130 mmHg systolic or/and >80 mmHg diastolic)
- history or clinical significant signs of heart, lung, liver, kidney, endocrine, brain or neoplastic disease.
- alcohol abuse
- drug abuse
- smoking
- pregnancy or nursing
- blood donation within a month prior to examination
- Medical treatment apart from oral contraception
Patients with chronic kidney disease
- clinical significant signs of heart, lung, liver, endocrine, brain or neoplastic disease.
- diabetes
- immunosuppressive medications
- smoking
- alcohol abuse
- drug abuse
- pregnancy or nursing
Sites / Locations
- Medical Research
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
hypertonic saline
Arm Description
hypertonic saline 3.0% (7 ml/kg)
Outcomes
Primary Outcome Measures
urinary biomarkers
Urinary epithelial sodium channels (ENaC), Sodium-potassium-2chloride transporters (NKCC) and aquaporin2 channels (AQP2) before, during and after fluid infusion
Secondary Outcome Measures
vaso active hormones
plasma concentrations of: renin, Angiotensin II, aldosterone, Vasopressin, atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP)
extra-and intracellular volume
measured by body composition monitor at baseline and after intervention
Full Information
NCT ID
NCT01623661
First Posted
June 18, 2012
Last Updated
March 3, 2014
Sponsor
Regional Hospital Holstebro
1. Study Identification
Unique Protocol Identification Number
NCT01623661
Brief Title
Effect of Hypertonic Sodium Chloride on Urinary Biomarkers in Healthy Subjects and Patients With Chronic Kidney Disease
Acronym
CASE
Official Title
Effect of Intravenous Sodium Chloride on Urinary Biomarkers for Measurement of Sodium- and Water Channel Activity in the Nephron in Healthy Subject an Patients With Chronic Kidney Disease. A Case Control Study
Study Type
Interventional
2. Study Status
Record Verification Date
March 2014
Overall Recruitment Status
Completed
Study Start Date
December 2011 (undefined)
Primary Completion Date
April 2013 (Actual)
Study Completion Date
June 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Regional Hospital Holstebro
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Patients with chronic kidney disease (CKD) have a defect in the tubular reabsorption of sodium, and therefore the ability to excrete a sodium load is diminished compared to healthy subjects.
Urinary biomarkers reflects the water- and sodium-channel activity in the kidney and may be measured after an infusion with hypertonic saline in CKD patients and healthy subjects.
Detailed Description
The fractional sodium excretion is elevated as high as 10-20% In patients with chronic kidney disease (CKD) Changes in the sodium intake results in a slower expansion and/or reduction in extracellular fluid in CKD patients.
Urinary biomarkers reflects the kidneys transport of sodium and water in the nephron.
Changes in the sodium-and water channel activity is induced by intervention with hypertonic Saline (3.0%) The change in sodium-and water channel activity is followed by change in extracellular and intracellular fluid compartments and the plasma concentration of vasoactive hormones.
The purpose of this study is to investigate the changes in urinary biomarkers (u-NKCC2, u-ENaC-gamma and u-AQP2), the activity of the sodium-and water channels, the extra- and intracellular fluid compartments and the plasma concentration of Vasoactive hormones in patients with CKD and in healthy subjects.
Subjects and patients are examined during one examination day. Four days prior to the examination day the subjects consume a standardized diet based on the amount of sodium and calories. On the examination day the subjects receive an infusion with hypertonic saline.
Renal function is measured by renal clearance of 51Cr-EDTA. Urinary biomarkers (u-NKCC2, u-ENaC-gamma and u-AQP2) are measured to evaluate the activity of sodium channels in the nephron and changes in fluid compartments are measured by body composition monitor.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Nephropathy
Keywords
Nephrology, chronic kidney disease, sodium-channels, water-channels, BCM
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
47 (Actual)
8. Arms, Groups, and Interventions
Arm Title
hypertonic saline
Arm Type
Other
Arm Description
hypertonic saline 3.0% (7 ml/kg)
Intervention Type
Other
Intervention Name(s)
hypertonic saline
Other Intervention Name(s)
hypertonic NaCl
Intervention Description
hypertonic saline 3.0 % (7 ml/kg)
Primary Outcome Measure Information:
Title
urinary biomarkers
Description
Urinary epithelial sodium channels (ENaC), Sodium-potassium-2chloride transporters (NKCC) and aquaporin2 channels (AQP2) before, during and after fluid infusion
Time Frame
one day
Secondary Outcome Measure Information:
Title
vaso active hormones
Description
plasma concentrations of: renin, Angiotensin II, aldosterone, Vasopressin, atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP)
Time Frame
one day
Title
extra-and intracellular volume
Description
measured by body composition monitor at baseline and after intervention
Time Frame
6 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
healthy subjects
healthy males and females
age 18-70
BMI range 18,5-30,0 kg/m2
Patients with CKD
age 18-70
eGFR 15-60 ml/min
BMI range 18.5 - 30.0 kg/m2
Exclusion Criteria:
healthy subjects
hypertension (ie ambulatory BP >130 mmHg systolic or/and >80 mmHg diastolic)
history or clinical significant signs of heart, lung, liver, kidney, endocrine, brain or neoplastic disease.
alcohol abuse
drug abuse
smoking
pregnancy or nursing
blood donation within a month prior to examination
Medical treatment apart from oral contraception
Patients with chronic kidney disease
clinical significant signs of heart, lung, liver, endocrine, brain or neoplastic disease.
diabetes
immunosuppressive medications
smoking
alcohol abuse
drug abuse
pregnancy or nursing
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Erling B Pedersen, DMSc
Organizational Affiliation
Regional Hospital Holstebro
Official's Role
Study Director
Facility Information:
Facility Name
Medical Research
City
Holstebro
ZIP/Postal Code
7500
Country
Denmark
12. IPD Sharing Statement
Citations:
PubMed Identifier
24970686
Citation
Jensen JM, Mose FH, Kulik AE, Bech JN, Fenton RA, Pedersen EB. Abnormal urinary excretion of NKCC2 and AQP2 in response to hypertonic saline in chronic kidney disease: an intervention study in patients with chronic kidney disease and healthy controls. BMC Nephrol. 2014 Jun 26;15:101. doi: 10.1186/1471-2369-15-101.
Results Reference
derived
Learn more about this trial
Effect of Hypertonic Sodium Chloride on Urinary Biomarkers in Healthy Subjects and Patients With Chronic Kidney Disease
We'll reach out to this number within 24 hrs